Search Results

You are looking at 31 - 40 of 71 items for :

Clear All
Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson and Peter Westervelt

. Hematopoietic cytokine support should be considered for refractory symptomatic cytopenias. 44 For example, recombinant human granulocyte colony stimulating factor (G-CSF) or granulocyte-monocyte CSF (GM-CSF) treatment could be considered for neutropenic

Full access

David D. Chism

median overall survival (OS) of 12.5 versus 8.2 months, albeit with greater toxicity. 4 A phase III randomized trial comparing dose-dense MVAC with granulocyte colony-stimulating factor (G-CSF) every 2 weeks versus standard MVAC showed a benefit in

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia and Gary H. Lyman

chemotherapy course. 20 , 23 An RDI less than 85% is generally considered to be a clinically significant reduction from standard or planned therapy. 8 , 10 , 12 , 20 , 24 Prophylactic granulocyte colony-stimulating factor (G-CSF) use has been shown in

Full access

Raymond L. Comenzo

sequential GM+G-CFS or G-CSF alone to treat AL (amyloid light chain) amyloidosis . Br J Haematol 1999 ; 104 : 553 – 559 . 47. Lewis WD Skinner M Simms RW . Orthotopic liver transplantation for familial amyloidotic polyneuropathy . Clin

Full access

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro and Gary H. Lyman

with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model . Br J Haematol 1997 ; 99 : 344 – 351 . 10. Casadevall N Durieux P Dubois S . Health, economic, and quality

Full access

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes and Fernando Rivera

.6%). Granulocyte colony-stimulating factor (G-CSF) prophylaxis was used in 36.2% of triplets versus 12% of doublets ( P <.0001). Treatment-related death occurred in 2 triplet-treated patients and 1 doublet-treated patient. Figure 2. Overall survival, 11

Full access

Patrick A. Brown, Matthew Wieduwilt, Aaron Logan, Daniel J. DeAngelo, Eunice S. Wang, Amir Fathi, Ryan D. Cassaday, Mark Litzow, Anjali Advani, Patricia Aoun, Bhavana Bhatnagar, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Peter F. Coccia, Steven E. Coutre, Nitin Jain, Suzanne Kirby, Arthur Liu, Stephanie Massaro, Ryan J. Mattison, Olalekan Oluwole, Nikolaos Papadantonakis, Jae Park, Jeffrey E. Rubnitz, Geoffrey L. Uy, Kristina M. Gregory, Ndiya Ogba and Bijal Shah

younger patients, largely due to high induction-related mortality (50%), contributing to a median OS of 1 month in this population. 28 The CALGB 9111 study evaluated the impact of adding granulocyte colony-stimulating factor (G-CSF) on neutrophil recovery

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman and Eunice S. Wang

past decade. The representative regimens include 1) cladribine, Ara-C, and granulocyte colony-stimulating factor (G-CSF) with or without mitoxantrone or idarubicin 72 , 73 ; 2) fludarabine, Ara-C, G-CSF with or without idarubicin 74 , 75 ; and 3

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Salil Goorha, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, Eunice S. Wang, Maoko Naganuma and Kristina M. Gregory

.S. cooperative group trials in the past decade. The representative regimens included are: 1) cladribine, cytarabine, and granulocyte colony-stimulating factor (G-CSF), with or without mitoxantrone or idarubicin 102 , 103 ; 2) fludarabine, cytarabine, and G-CSF

Full access

). ASCO guidelines summarize current data on the appropriate use of granulocyte CSF (G-CSF) prophylaxis. A single-center retrospective study was undertaken to evaluate oncologist compliance with ASCO guidelines, and to determine whether noncompliance